FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

NCT03721653 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

218

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Bevacizumab
DRUG: Irinotecan
DRUG: Oxaliplatin
DRUG: L-Leucovorin
DRUG: 5-fluorouracil
DRUG: Atezolizumab

Sponsor

Gruppo Oncologico del Nord-Ovest

Collaborators

[object Object]